Brain atrophy and disability progression in multiple sclerosis patients: A 10-year follow-up study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 10, 2014, Pages 1109-1115

  Jacobsen, Cecilie ^a,b,c   Hagemeier, Jesper ^b   Myhr, Kjell Morten ^c,d   Nyland, Harald ^c,d   Lode, Kirsten ^a   Bergsland, Niels ^b   Ramasamy, Deepa P ^b   Dalaker, Turi O ^a,c   Larsen, Jan Petter ^c   Farbu, Elisabeth ^a,c   Zivadinov, Robert ^b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; COHORT ANALYSIS; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PUTAMEN; WHITE MATTER; ATROPHY; BRAIN; MYELINATED NERVE; NEUROIMAGING; NONMYELINATED NERVE; PATHOLOGY;

MULTIPLE SCLEROSIS;

ADULT; ATROPHY; BRAIN; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED; NERVE FIBERS, UNMYELINATED; NEUROIMAGING;

EID: 84908326865     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-306906     Document Type: Article

References (46)

1. Bo L, Geurts JJ, Mork SJ, et al. Grey matter pathology in multiple sclerosis. Acta Neurol Scand Suppl 2006; 183:48-50.
2. Hulst HE, Geurts JJ. Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol 2011; 11:153.
3. Popescu BF, Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol 2012; 12:11.
4. Seewann A, Kooi EJ, Roosendaal SD, et al. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 2012; 78:302-8.
5. Geurts JJ, Calabrese M, Fisher E, et al. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012; 11:1082-92.
6. Zivadinov R, Bergsland N, Dolezal O, et al. Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. AJNR Am J Neuroradiol 2013; 34:1931-9.
7. Zivadinov R, Havrdova E, Bergsland N, et al. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013; 268:831-41.
8. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59:1412-20.
9. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008; 64:247-54.
10. Horakova D, Dwyer MG, Havrdova E, et al. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. J Neurol Sci 2009; 282:112-19.
11. Rudick RA, Lee JC, Nakamura K, et al. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci 2009; 282:106-11.
12. Sastre-Garriga J, Ingle GT, Chard DT, et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain 2005; 128:1454-60.
13. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127:1101-7.
14. Bergsland N, Horakova D, Dwyer MG, et al. Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. AJNR. Am J Neuroradiol 2012; 33:1573-8.
15. Calabrese M, Rinaldi F, Mattisi I, et al. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011; 77:257-63.
16. Henry RG, Shieh M, Okuda DT, et al. Regional Grey Matter Atrophy in Clinically Isolated Syndromes at Presentation. J Neurol Neurosurg Psychiatry 2008; 79:1236-44.
17. Fisher E, Lee JC, Nakamura K, et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008; 64:255-65.
18. Neema M, Arora A, Healy BC, et al. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 2009; 19:3-8.
19. Lukas C, Minneboo A, de Groot V, et al. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81:1351-6.
20. Roosendaal SD, Bendfeldt K, Vrenken H, et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler 2011; 17:1098-106.
21. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227-31.
22. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-52.
23. Jenkinson M, Bannister P, Brady M, et al. Improved optimization for the robust and accurate linear registration and motion correction of brain images. NeuroImage 2002; 17:825-41.
24. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57:1239-47.
25. Zivadinov R, Heininen-Brown M, Schirda CV, et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. NeuroImage 2012; 59:331-9.
26. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage 2002; 17:479-89.
27. Dwyer MG, Bergsland N, Zivadinov R. Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model. NeuroImage 2013.
28. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001; 20:45-57.
29. Patenaude B, Smith SM, Kennedy DN, et al. A Bayesian model of shape and appearance for subcortical brain segmentation. NeuroImage 2011; 56:907-22.
30. Zivadinov R, Reder A, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71:136-44.
31. Minagar A, Barnett MH, Benedict RH, et al. The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology 2013; 80:210-9.
32. Pirko I, Lucchinetti CF, Sriram S, et al. Gray matter involvement in multiple sclerosis. Neurology 2007; 68:634-42.
33. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003; 60:1157-62.
34. Tiberio M, Chard DT, Altmann DR, et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 2005; 64:1001-7.
35. Ramasamy DP, Benedict RH, Cox JL, et al. Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J Neurol Sci 2009; 282:47-54.
36. Chard DT, Griffin CM, Parker GJ, et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125:327-37.
37. Ge Y, Grossman RI, Udupa JK, et al. Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter. Radiology 2001; 220:606-10.
38. Gelineau-Morel R, Tomassini V, Jenkinson M, et al. The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapp 2012; 33:2802-14.
39. Horakova D, Cox JL, Havrdova E, et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. J Neurol Neurosurg Psychiatry 2008; 79:407-14.
40. Zivadinov R, Pirko I. Advances in understanding gray matter pathology in multiple sclerosis: Are we ready to redefine disease pathogenesis? BMC Neurol 2012; 12:9.
41. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006; 5:158-70.
42. Zivadinov R, Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 2004; 14:27S-35S.
43. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69:292-302.
44. Caramanos Z, Francis SJ, Narayanan S, et al. Large, nonplateauing relationship between clinical disability and cerebral white matter lesion load in patients with multiple sclerosis. Arch Neurol 2012; 69:89-95.
45. Popescu V, Agosta F, Hulst HE, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013; 84:1082-91.
46. Bendfeldt K, Hofstetter L, Kuster P, et al. Longitudinal gray matter changes in multiple sclerosis-differential scanner and overall disease-related effects. Hum Brain Mapp 2012; 33:1225-45.